PCR technology

Diagnostic testing at the

point of care

Confidently identify the viruses that are circulating at the highest prevalence this respiratory season—Nobel Prize-winning technology, at your fingertips

One swab, multiple results

Singleplex and
multiplex assays

• cobas® SARS-CoV-2 &
  Influenza A/B
• cobas® Influenza A/B + RSV
• cobas® SARS-CoV-2
• cobas® Strep A
• cobas® C. diff^†

Definitive results

Who needs a second test?

• Definitive results in just 15–20 minutes, allowing for test to treat in one visit*
• CLIA-waived tests provide accurate results wherever patient care is needed^†

Announcing our submission to the U.S. FDA for Emergency Use Authorization for cobas® liat SARS-CoV-2, Influenza A/B & RSV¹

1: This product is pending FDA review and is not available for sale in the US

† cobas® Cdiff has been cleared by the FDA for use by authorized laboratories certified under CLIA to perform moderate complexity testing.

* cobas® SARS-CoV-2 & Influenza A/B assay: If sample results indicate co-infection of SARS-CoV-2 with Influenza A or Influenza B and a positive influenza result would change clinical management, the sample should be re-tested with a second FDA cleared or EUA influenza test. cobas® SARS-CoV-2 assay: A negative result from an asymptomatic individual is presumptive. See package insert for details.